TSE:ONC

Oncolytics Biotech (ONC) Stock Forecast, Price & News

C$2.28

+0.04 (+1.79%)

(As of 06/2/2023 ET)

Compare

Today's Range: C$2.21
▼
C$2.30
50-Day Range: C$1.51
▼
C$2.93
52-Week Range: C$1.06
▼
C$3.10

Volume: 103,672 shs
Average Volume: 55,145 shs
Market Capitalization: C$146.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$6.75

Profile Analyst Ratings Chart Competitors Earnings Insider Trades Headlines Social Media

Oncolytics Biotech MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 196.1% Upside
C$6.75 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.45
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Oncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$6.75, Oncolytics Biotech has a forecasted upside of 196.1% from its current price of C$2.28.
Amount of Analyst Coverage
Oncolytics Biotech has only been the subject of 3 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for ONC.

0.0

Dividend Strength

Dividend Yield
Oncolytics Biotech does not currently pay a dividend.
Dividend Growth
Oncolytics Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ONC.

1.4

News and Social Media Coverage

News Sentiment
Oncolytics Biotech has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Oncolytics Biotech this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
2 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.34% of the stock of Oncolytics Biotech is held by insiders.
Percentage Held by Institutions
Only 1.47% of the stock of Oncolytics Biotech is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Oncolytics Biotech is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oncolytics Biotech is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oncolytics Biotech has a P/B Ratio of 5.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONC Stock News Headlines

May 31, 2023 | baystreet.ca

Significant Oncology Results Set to be Delivered as Oral Presentations at ASCO 2023

May 27, 2023 | americanbankingnews.com

Oncolytics Biotech (TSE:ONC) PT Set at C$9.00 by Jonestrading

June 3, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 26, 2023 | msn.com

Oncolytics Biotech Dives after Breast Cancer Treatment Disappoints

May 26, 2023 | msn.com

Oncolytics falls 16% after mid-stage data for breast cancer therapy

May 26, 2023 | finanznachrichten.de

USA News Group: Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

May 25, 2023 | finance.yahoo.com

Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

May 24, 2023 | finance.yahoo.com

CANADA STOCKS-TSX tumbles as bank earnings, US debt deal uncertainty weigh

June 3, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

May 24, 2023 | baystreet.ca

TSX Sinks into the Red

May 24, 2023 | benzinga.com

Oncolytics Biotech shares are trading higher after JonesTrading initiated covered on the stock with a Buy rating and announced a $9 price target.

May 21, 2023 | americanbankingnews.com

Oncolytics Biotech (TSE:ONC) Stock Price Passes Above Two Hundred Day Moving Average of $2.09

May 13, 2023 | americanbankingnews.com

FY2027 EPS Estimates for Oncolytics Biotech Inc. (TSE:ONC) Increased by Analyst

May 12, 2023 | americanbankingnews.com

Q2 2023 Earnings Forecast for Oncolytics Biotech Inc. (TSE:ONC) Issued By HC Wainwright

May 10, 2023 | finanznachrichten.de

Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

May 9, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY) and Senseonics Holdings (SENS)

May 7, 2023 | finance.yahoo.com

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2023 Earnings Call Transcript

May 6, 2023 | ca.finance.yahoo.com

Stocks in play: Oncolytics Biotech

May 5, 2023 | benzinga.com

Oncolytics Biotech Says Cash Balance Of C$29.7M Is Expected To Provide Projected Cash Runway For At Least 12 Months

May 5, 2023 | msn.com

Oncolytics Biotech: Q1 Earnings Insights

May 5, 2023 | finance.yahoo.com

Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights

May 4, 2023 | americanbankingnews.com

Oncolytics Biotech (ONC) Set to Announce Quarterly Earnings on Friday

May 3, 2023 | marketwatch.com

Oncolytic Virus Therapy Market : Competitive Strategy Analysis and Forecast Values 2023-2031

April 27, 2023 | marketwatch.com

Global Oncolytic Virus Therapy Market by [2023-2029] with Revenue Outsourcing

April 26, 2023 | finance.yahoo.com

Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting

April 25, 2023 | markets.businessinsider.com

Oncolytic Virus Therapies Market Size Worth USD 609.7 Million in 2028 - Emergen Research

April 12, 2023 | finanznachrichten.de

Oncolytics Biotech® Inc.: Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

See More Headlines

ONC Price History

30 days | 90 days | 365 days | Advanced Chart

ONC Company Calendar

Today: 6/02/2023
Next Earnings (Estimated): 8/10/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:ONC
CUSIP: N/A
CIK: N/A
Web: www.oncolyticsbiotech.com
Phone: +1-403-6707380
Fax: N/A
Employees: 26
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: C$6.75
High Stock Price Forecast: C$9.00
Low Stock Price Forecast: C$3.00
Forecasted Upside/Downside: +196.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): C($0.42)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-24,490,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -80.61%
Return on Assets: -42.85%

Debt

Debt-to-Equity Ratio: 2.20
Current Ratio: 13.88
Quick Ratio: 8.86

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$0.54 per share
Price / Cash Flow: 4.22
Book Value: C$0.40 per share
Price / Book: 5.70

Miscellaneous

Outstanding Shares: 64,090,000
Free Float: N/A
Market Cap: C$146.13 million
Optionable: Not Optionable
Beta: 1.79

Key Executives

Dr. Matthew C. Coffey M.B.A.
Ph.D., Pres, CEO & Director

Mr. Kirk J. Look C.A.
CA, Chief Financial Officer

Mr. Andrew R. de Guttadauro (Age 55)
Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc
Comp: $558.94k

Dr. Thomas C. Heineman M.D.
Ph.D., Chief Medical Officer

Ms. Allison Hagerman P.Eng.
P.M.P., VP of Product Devel.

Jon Patton
Director of Investor Relations & Communication

Dr. Grey Wilkinson Ph.D.
Scientist of Translational Medicine

Mr. John Mark Lievonen F.C.A.
FCA, Consultant

Dr. Daniel Douglas Von Hoff F.A.C.P. (Age 74)
FACP, M.D., Consultant

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ONC Stock - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONC shares.
View ONC analyst ratings or view top-rated stocks.
What is Oncolytics Biotech's stock price forecast for 2023?: 5 brokers have issued 1 year price targets for Oncolytics Biotech's shares. Their ONC share price forecasts range from C$3.00 to C$9.00. On average, they expect the company's share price to reach C$6.75 in the next twelve months. This suggests a possible upside of 196.1% from the stock's current price.
View analysts price targets for ONC or view top-rated stocks among Wall Street analysts.
How have ONC shares performed in 2023?: Oncolytics Biotech's stock was trading at C$2.22 at the beginning of 2023. Since then, ONC shares have increased by 2.7% and is now trading at C$2.28.
View the best growth stocks for 2023 here.
When is Oncolytics Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ONC earnings forecast.

What other stocks do shareholders of Oncolytics Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR).
What is Oncolytics Biotech's stock symbol?: Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."
How do I buy shares of Oncolytics Biotech?: Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Oncolytics Biotech's stock price today?: One share of ONC stock can currently be purchased for approximately C$2.28.
How much money does Oncolytics Biotech make?: Oncolytics Biotech (TSE:ONC) has a market capitalization of C$146.13 million. The company earns C$-24,490,000.00 in net income (profit) each year or C($0.42) on an earnings per share basis.
How can I contact Oncolytics Biotech?: Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The official website for the company is www.oncolyticsbiotech.com. The company can be reached via phone at +1-403-6707380.

This page (TSE:ONC) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oncolytics Biotech (ONC) Stock Forecast, Price & News

Oncolytics Biotech MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Oncolytics Biotech (TSE:ONC) Stock

ONC Stock News Headlines

ONC Price History

ONC Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

ONC Stock - Frequently Asked Questions

Overall MarketRank^™